Expansion opportunities Fannin's recent launches of morcellators and an AI-assisted pancreatic EUS tool, along with hosting specialized morcellation masterclasses, indicate active product expansion and education-driven growth. This creates cross-sell and upsell opportunities to existing customers in gynecologic procedures and endoscopy, as well as prospects seeking training-enabled adoption.

Strategic partnerships Ongoing distribution and strategic partnerships with Medovate, HPNE, and MyBio highlight a channel-rich approach. Sales teams can target healthcare facilities and distributors seeking comprehensive portfolios or regional exclusivity, leveraging Fannin’s broadened product suite and co-marketing potential.

Regional focus Headquartered in South Dublin with UK and Ireland operations and a track record of international recognition, Fannin is well-positioned for cross-border selling in the UK and Ireland. Leverage regional procurement cycles, clinical training events, and national health programs to drive new product adoptions.

Clinical credibility Maintaining ISO 13485 compliance and a portfolio spanning devices, diagnostics, and pharmaceuticals reinforces reliability and quality. This supports value-based selling with hospital procurement teams, emphasizing patient outcomes, regulatory alignment, and long-term service contracts.

Growth signals Recent awards and product introductions signal a growth trajectory supported by acquisitions and innovation. Use this momentum to approach hospitals and distributors with bundled offerings, implementation support, and training packages that reduce adoption risk and accelerate time-to-revenue.